Modified gemcitabine and oxaliplatin or gemcitabine plus cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial

Sharma Atul; Mohanti Bidhu Kalyan; Chaudhary Surendra Pal; Sreenivas V.; Sahoo Ranjit Kumar; Shukla Nootan Kumar; Thulkar Sanjay; Pal Sujoy; Deo Surya V.; Pathy Sushmita; Dash Nihar Ranjan; Kumar Sunil; Bhatnagar Sushma; Kumar Rakesh; Mishra Seema; Sahni Peush; Iyer Venkateswaran K.; Raina Vinod

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Modified gemcitabine and oxaliplatin or gemcitabine plus cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial

【24h】

Modified gemcitabine and oxaliplatin or gemcitabine plus cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial

机译：改进的吉西他滨和奥氏牛肝蛋白或吉西他滨加顺铂在不可切除的胆囊癌中：III期随机对照试验的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: To determine equivalence of modified gemcitabine and oxaliplatin compared with gemcitabine and cisplatin in unresectable gallbladder cancer (GBC). Primary end-point was overall survival (OS).

机译：目的：与吉西他滨和顺铂相比，确定改良吉西他滨和奥沙利铂的等价性（GBC）。初级终点是整体存活（OS）。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2019年第2019期|共9页
作者
Sharma Atul; Mohanti Bidhu Kalyan; Chaudhary Surendra Pal; Sreenivas V.; Sahoo Ranjit Kumar; Shukla Nootan Kumar; Thulkar Sanjay; Pal Sujoy; Deo Surya V.; Pathy Sushmita; Dash Nihar Ranjan; Kumar Sunil; Bhatnagar Sushma; Kumar Rakesh; Mishra Seema; Sahni Peush; Iyer Venkateswaran K.; Raina Vinod;
展开▼
作者单位

AIIMS Dept Med Oncol Dr BRA IRCH New Delhi 110029 India;

AIIMS Dept Radiat Oncol Dr BRA IRCH New Delhi 110029 India;

AIIMS Dept Med Oncol Dr BRA IRCH New Delhi 110029 India;

AIIMS Dept Biostat New Delhi 110029 India;

AIIMS Dept Med Oncol Dr BRA IRCH New Delhi 110029 India;

AIIMS Dept Surg Oncol Dr BRA IRCH New Delhi 110029 India;

AIIMS Dept Radio Diag Dr BRA IRCH New Delhi 110029 India;

AIIMS Dept Gastrointestinal Surg &

Liver Transplantat New Delhi 110029 India;

AIIMS Dept Surg Oncol Dr BRA IRCH New Delhi 110029 India;

AIIMS Dept Radiat Oncol Dr BRA IRCH New Delhi 110029 India;

AIIMS Dept Gastrointestinal Surg &

Liver Transplantat New Delhi 110029 India;

AIIMS Dept Surg Oncol Dr BRA IRCH New Delhi 110029 India;

AIIMS Dr BRA IRCH Dept Oncoanaesthesia &

Palliat Med New Delhi 110029 India;

AIIMS Dept Nucl Med New Delhi 110029 India;

AIIMS Dept Nucl Med New Delhi 110029 India;

AIIMS Dept Gastrointestinal Surg &

Liver Transplantat New Delhi 110029 India;

AIIMS Dept Pathol New Delhi 110029 India;

AIIMS Dept Med Oncol Dr BRA IRCH New Delhi 110029 India;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Gallbladder cancer; Gemcitabine; Oxaliplatin; Cisplatin; Equivalence;

机译：胆囊癌;吉西他滨;oxaliplatin;顺铂;等价;

相似文献

外文文献
中文文献
专利

1. Modified gemcitabine and oxaliplatin or gemcitabine plus cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial [J] . Sharma Atul, Mohanti Bidhu Kalyan, Chaudhary Surendra Pal, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：改进的吉西他滨和奥氏牛肝蛋白或吉西他滨加顺铂在不可切除的胆囊癌中：III期随机对照试验的结果
2. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial [J] . Thatcher Nick, Hirsch Fred R., Luft Alexander V., The lancet oncology . 2015,第7期

机译：尼妥单抗联合吉西他滨和顺铂与吉西他滨和顺铂单独作为IV期鳞状非小细胞肺癌（SQUIRE）患者的一线治疗：一项开放标签，随机，对照的3期试验
3. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial [J] . Thatcher Nick, Hirsch Fred R., Luft Alexander V., The lancet oncology . 2015,第7期

机译：尼妥单抗联合吉西他滨和顺铂与吉西他滨和顺铂单独作为IV期鳞状非小细胞肺癌（SQUIRE）患者的一线治疗：一项开放标签，随机，对照的3期试验
4. Gemcitabine + Cisplatin Combination Electrochemotherapy for Triple Negative Breast Cancers: An in vitro Model Study [C] . R. Sundararajan, V. Raman, V. Masterson World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food Environmental Technologies . 2016

机译：Gemcitabine +顺铂组合电化学疗法三重阴性乳腺癌：体外模型研究
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer [O] . Sang Myung Woo, Sang Hyub Lee, Ji Won Yoo, 2013

机译：吉西他滨联合奥沙利铂治疗无法切除的胆囊癌的多中心II期试验
7. Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B Unresectable Non-small Cell Lung Cancer [O] . Movsas Benjamin, Langer Corey J., Ross Helen J., 2010

机译：顺铂，依托泊苷和放射治疗的II期随机试验，继之单独的吉西他滨或吉西他滨与多西他赛联合治疗IIIA / B期不可切除的非小细胞肺癌

Modified gemcitabine and oxaliplatin or gemcitabine plus cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅